Epimed Gesellschaft fuer epidemiologische und klinische Forschung in der Medizin mbH
- Address
- lock Available on a paid plan
Virus Diseases and HIV Research
At Epimed Gesellschaft fuer epidemiologische und klinische Forschung in der Medizin mbH in Berlin, clinical research in virus diseases focuses on HIV-1 infection. These studies are centered on evaluating new treatment options and comparing how well they control the virus while maintaining good safety and tolerability.
- Antiretroviral treatment for people living with HIV-1
- Comparing treatment effectiveness against established therapy
- Monitoring safety and long-term tolerability
The site’s work in this area supports better treatment choices for patients and contributes to ongoing progress in HIV care.
Nutritional and Metabolic Diseases and Liver Disease Research
Clinical trials in nutritional and metabolic diseases at this research site address Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Non Alcoholic Steatohepatitis (NASH), including cases with fibrosis. The research is aimed at testing whether new therapies can improve liver health, reduce disease progression, and support meaningful clinical outcomes.
- Investigating treatment options for NASH and MASH
- Assessing improvement in fibrosis and liver-related outcomes
- Evaluating potential benefits for long-term disease control
This work reflects a strong interest in therapies that may help slow or reverse serious metabolic liver disease.
Preventive Infectious Disease Research
Another important area at Epimed Gesellschaft fuer epidemiologische und klinische Forschung in der Medizin mbH involves prevention of oral persistent infection caused by multiple human papillomavirus types, including 16, 18, 31, 33, 45, 52, and 58. The trial activity in this field is focused on evaluating whether vaccination can reduce infection rates and strengthen disease prevention.
- Studying prevention of HPV-related oral infection
- Assessing the protective value of vaccination
- Supporting public health efforts in viral prevention
These studies highlight the site’s contribution to infectious disease prevention and broader efforts to reduce virus-related health risks.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 of 7 therapeutic areas and 15 of 49 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Epimed Gesellschaft fuer epidemiologische und klinische Forschung in der Medizin mbH
lock Showing 1 of 19 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b Randomized, Open-Label Active Controlled Study Evaluating the Safety and Efficacy of oral VH4524184 Coadministered with Emtricitabine and Tenofovir Alafenamide in Treatment Naïve Viremic Persons with HIV-1.( INNOVATE Study) | Viiv Healthcare UK Limited | Phase II | Recruiting | Feb 2026 | — |
IMP list
lock Showing 1 of 49 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Emtricitabine | 5 | Unknown | 2024-02-14 | 2026-02-11 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.